FDA approves Lilly oral GLP-1 Foundayo for weight loss

April 1: FDA green-lights Eli Lilly's orforglipron (Foundayo), the first oral GLP-1 for obesity—no food or water restrictions, take anytime. ATTAIN-1 top dose averaged 12.4% weight loss (27.3 lb); launch pricing $149/month cash, $25/month commercial insurance.